Ras-related protein 1 and the insulin-like growth factor type i receptor are associated with risk of progression in patients diagnosed with carcinoma in situ

Breast Cancer Research and Treatment

Volumn 129, Issue 2, 2011, Pages 361-372

  Furstenau, Dana K ^a   Mitra, Nandita ^a   Wan, Fei ^a   Lewis, Robert ^a   Feldman, Michael D ^a   Fraker, Douglas L ^a   Guvakova, Marina A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breast; Cancer in situ; IGF IR; Invasion; Small GTPase Rap1

Indexed keywords

RAP1 PROTEIN; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BREAST CARCINOMA; BREAST CARCINOMA IN SITU; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMAGE BASED UNIPLEX METHOD; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK REDUCTION;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM INVASIVENESS; ODDS RATIO; PHILADELPHIA; PROGNOSIS; RAP GTP-BINDING PROTEINS; RECEPTOR, IGF TYPE 1; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 80052645527     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1227-y     Document Type: Article

References (62)

1. CJ Allegra DR Aberle P Ganschow SM Hahn CN Lee S Millon-Underwood MC Pike SD Reed AF Saftlas SA Scarvalone AM Schwartz C Slomski G Yothers R Zon 2010 National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ September 22-24, 2009 J Natl Cancer Inst 102 161 169 20071686 10.1093/jnci/djp485
2. K Kerlikowske AM Molinaro ML Gauthier HK Berman F Waldman J Bennington H Sanchez C Jimenez K Stewart K Chew BM Ljung TD Tlsty 2010 Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis J Natl Cancer Inst 102 627 637 20427430 10.1093/jnci/djq101 1:CAS:528: DC%2BC3cXlvVWqtrw%3D
3. HM Kuerer CT Albarracin WT Yang RD Cardiff AM Brewster WF Symmans NM Hylton LP Middleton S Krishnamurthy GH Perkins G Babiera ME Edgerton BJ Czerniecki BK Arun GN Hortobagyi 2009 Ductal carcinoma in situ: state of the science and roadmap to advance the field J Clin Oncol 27 279 288 19064970 10.1200/JCO.2008.18.3103
4. LE Hoorntje ME Schipper PH Peeters F Bellot RK Storm RI Borel 2003 The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in situ: causes of ductal carcinoma-in situ underestimates with stereotactic 14-gauge needle biopsy Ann Surg Oncol 10 748 753 12900365 10.1245/ASO.2003.11. 011 (Pubitemid 40486874)
5. L Huo N Sneige KK Hunt CT Albarracin A Lopez E Resetkova 2006 Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ Cancer 107 1760 1768 16977650 10.1002/cncr.22216 (Pubitemid 44582944)
6. P Meijnen HS Oldenburg CE Loo OE Nieweg JL Peterse EJ Rutgers 2007 Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy Br J Surg 94 952 956 17440955 10.1002/bjs.5735 1:STN:280:DC%2BD2svisF2isw%3D%3D (Pubitemid 47236538)
7. AA Renshaw 2002 Predicting invasion in the excision specimen from breast core needle biopsy specimens with only ductal carcinoma in situ Arch Pathol Lab Med 126 39 41 11800645 (Pubitemid 34087630)
8. RE Roses EC Paulson A Sharma JE Schueller H Nisenbaum S Weinstein KR Fox PJ Zhang BJ Czerniecki 2009 HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer Cancer Epidemiol Biomarkers Prev 18 1386 1389 19383888 10.1158/1055-9965.EPI-08-1101 1:CAS:528: DC%2BD1MXlsFCltrk%3D
9. EC Kohn EA Francis LA Liotta E Schiffmann 1990 Heterogeneity of the motility responses in malignant tumor cells: a biological basis for the diversity and homing of metastatic cells Int J Cancer 46 287 292 2116998 10.1002/ijc.2910460225 1:STN:280:DyaK3czks1ClsA%3D%3D (Pubitemid 20252092)
10. ME Doerr JI Jones 1996 The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells J Biol Chem 271 2443 2447 8576205 10.1074/jbc.271.5.2443 1:CAS:528:DyaK28XptVKmtA%3D%3D (Pubitemid 26047847)
11. MA Guvakova E Surmacz 1997 Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells Exp Cell Res 231 149 162 9056422 10.1006/excr.1996.3457 1:CAS:528:DyaK2sXhsVKktL4%3D (Pubitemid 27187524)
12. M Shakibaei T John P De Souza R Rahmanzadeh HJ Merker 1999 Signal transduction by beta1 integrin receptors in human chondrocytes in vitro: collaboration with the insulin-like growth factor-I receptor Biochem J 342 Pt 3 615 623 10477272 10.1042/0264-6021:3420615 1:CAS:528:DyaK1MXmsVygs78%3D (Pubitemid 29452646)
13. K Vuori E Ruoslahti 1994 Association of insulin receptor substrate-1 with integrins Science 266 1576 1578 7527156 10.1126/science.7527156 1:CAS:528:DyaK2MXisVGlsrk%3D
14. T Lopez D Hanahan 2002 Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis Cancer Cell 1 339 353 12086849 10.1016/S1535-6108(02)00055-7 1:CAS:528:DC%2BD38XktlSrtLc%3D (Pubitemid 41039136)
15. C All-Ericsson L Girnita S Seregard A Bartolazzi MJ Jager O Larsson 2002 Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target Invest Ophthalmol Vis Sci 43 1 8 11773005 (Pubitemid 34032432)
16. P Brodt A Samani R Navab 2000 Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy Biochem Pharmacol 60 1101 1107 11007947 10.1016/S0006-2952(00)00422-6 1:CAS:528:DC%2BD3cXmslOjsb0%3D
17. JG Jackson X Zhang T Yoneda D Yee 2001 Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines Oncogene 20 7318 7325 11704861 10.1038/sj.onc.1204920 1:CAS:528:DC%2BD3MXovVOntL0%3D (Pubitemid 33078202)
18. I Nishizuka T Ishikawa Y Hamaguchi M Kamiyama Y Ichikawa K Kadota R Miki Y Tomaru Y Mizuno N Tominaga R Yano H Goto H Nitanda S Togo Y Okazaki Y Hayashizaki H Shimada 2002 Analysis of gene expression involved in brain metastasis from breast cancer using cDNA microarray Breast Cancer 9 26 32 12196718 10.1007/BF02967543
19. LC Happerfield DW Miles DM Barnes LL Thomsen P Smith A Hanby 1997 The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue J Pathol 183 412 417 9496257 10.1002/(SICI)1096- 9896(199712)183:4<412::AID-PATH944>3.0.CO;2-4 1:STN:280: DyaK1c7lslensA%3D%3D (Pubitemid 27509247)
20. JL Resnik DB Reichart K Huey NJ Webster BL Seely 1998 Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer Cancer Res 58 1159 1164 9515800 1:CAS:528: DyaK1cXhvV2rsrs%3D (Pubitemid 28183203)
21. C Shimizu T Hasegawa Y Tani F Takahashi M Takeuchi T Watanabe M Ando N Katsumata Y Fujiwara 2004 Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis Hum Pathol 35 1537 1542 15619214 10.1016/j.humpath.2004.09.005 1:CAS:528:DC%2BD2cXhtVyku7%2FE (Pubitemid 40017995)
22. TO Nielsen HN Andrews M Cheang JE Kucab FD Hsu J Ragaz CB Gilks N Makretsov CD Bajdik C Brookes LM Neckers V Evdokimova DG Huntsman SE Dunn 2004 Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin Cancer Res 64 286 291 14729636 10.1158/0008-5472.CAN-03-1242 1:CAS:528:DC%2BD2cXkslyktg%3D%3D (Pubitemid 38114109)
23. KL van Golen 2003 Inflammatory breast cancer: relationship between growth factor signaling and motility in aggressive cancers Breast Cancer Res 5 174 179 12793901 10.1186/bcr598 (Pubitemid 36519413)
24. MM Chitnis JS Yuen AS Protheroe M Pollak VM Macaulay 2008 The type 1 insulin-like growth factor receptor pathway Clin Cancer Res 14 6364 6370 18927274 10.1158/1078-0432.CCR-07-4879 1:CAS:528:DC%2BD1cXht1KgtbrP
25. D Romano M Pertuit R Rasolonjanahary JV Barnier K Magalon A Enjalbert C Gerard 2006 Regulation of the RAP1/RAF-1/extracellularly regulated kinase-1/2 cascade and prolactin release by the phosphoinositide 3-kinase/AKT pathway in pituitary cells Endocrinology 147 6036 6045 16935846 10.1210/en.2006-0325 1:CAS:528:DC%2BD28Xht1yqtrvM (Pubitemid 44833523)
26. Guvakova MA, Lee WSY (2009) Tuberin and hamartin in moving breast cancer cells expression localization and function. In: Abreu T, Silva G (eds) Cell movement new research trends. Nova Science Publishers, New York, pp 187-207
27. S Paganini GF Guidetti S Catricala P Trionfini S Panelli C Balduini M Torti 2006 Identification and biochemical characterization of Rap2C, a new member of the Rap family of small GTP-binding proteins Biochimie 88 285 295 16213650 10.1016/j.biochi.2005.08.007 1:CAS:528:DC%2BD28Xjs1aiu7s%3D
28. JL Bos J de Rooij KA Reedquist 2001 Rap1 signalling: adhering to new models Nat Rev Mol Cell Biol 2 369 377 11331911 10.1038/35073073 1:CAS:528:DC%2BD3MXjs1Chu7g%3D (Pubitemid 33674049)
29. GM Bokoch 1993 Biology of the Rap proteins, members of the ras superfamily of GTP-binding proteins Biochem J 289 Pt 1 17 24 8424755 1:CAS:528:DyaK3sXnsFCmtg%3D%3D (Pubitemid 23040802)
30. JL Bos 2005 Linking Rap to cell adhesion Curr Opin Cell Biol 17 123 128 15780587 10.1016/j.ceb.2005.02.009 1:CAS:528:DC%2BD2MXisVCqtLk%3D (Pubitemid 40380934)
31. E Caron 2003 Cellular functions of the Rap1 GTP-binding protein: a pattern emerges J Cell Sci 116 435 440 12508104 10.1242/jcs.00238 1:CAS:528:DC%2BD3sXhtlOgsro%3D (Pubitemid 36231283)
32. M Hattori N Minato 2003 Rap1 GTPase: functions, regulation, and malignancy J Biochem 134 479 484 14607972 10.1093/jb/mvg180 1:CAS:528: DC%2BD3sXhtVWgtb3K (Pubitemid 37442869)
33. EW Frische FJ Zwartkruis 2010 Rap1, a mercenary among the Ras-like GTPases Dev Biol 340 1 9 20060392 10.1016/j.ydbio.2009.12.043 1:CAS:528:DC%2BC3cXivFGrt74%3D
34. DH Gutmann S Saporito-Irwin JE De Clue R Wienecke A Guha 1997 Alterations in the rap1 signaling pathway are common in human gliomas Oncogene 15 1611 1616 9380414 10.1038/sj.onc.1201314 1:CAS:528:DyaK2sXmslyntLs%3D (Pubitemid 27464655)
35. WG Jiang J Sampson TA Martin L Lee-Jones G Watkins A Douglas-Jones K Mokbel RE Mansel 2005 Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes Eur J Cancer 41 1628 1636 15951164 10.1016/j.ejca.2005.03.023 1:CAS:528:DC%2BD2MXmsVCmurk%3D (Pubitemid 40981846)
36. L Zhang L Chenwei R Mahmood K van Golen J Greenson G Li NJ D'Silva X Li CF Burant CD Logsdon DM Simeone 2006 Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer Cancer Res 66 898 906 16424023 10.1158/0008-5472.CAN-05-3025 1:CAS:528:DC%2BD28XlsFOqsQ%3D%3D (Pubitemid 43165956)
37. A Nellore K Paziana C Ma OM Tsygankova Y Wang K Puttaswamy AU Iqbal SR Franks Y Lv AB Troxel MD Feldman JL Meinkoth MS Brose 2009 Loss of Rap1GAP in papillary thyroid cancer J Clin Endocrinol Metab 94 1026 1032 19066305 10.1210/jc.2008-1042 1:CAS:528:DC%2BD1MXjt1WmtLs%3D
38. V Yajnik C Paulding R Sordella AI McClatchey M Saito DC Wahrer P Reynolds DW Bell R Lake S Heuvel Van, den J Settleman DA Haber 2003 DOCK4, a GTPase activator, is disrupted during tumorigenesis Cell 112 673 684 12628187 10.1016/S0092-8674(03)00155-7 1:CAS:528:DC%2BD3sXitFyku74%3D (Pubitemid 36331779)
39. T Hirata H Nagai K Koizumi K Okino A Harada M Onda T Nagahata I Mikami K Hirai S Haraguchi E Jin O Kawanami K Shimizu M Emi 2004 Amplification, up-regulation and over-expression of C3G (CRK SH3 domain-binding guanine nucleotide-releasing factor) in non-small cell lung cancers J Hum Genet 49 6 290 295 15138850 10.1007/s10038-004-0148-1 1:CAS:528:DC%2BD2cXkvVOiur8%3D (Pubitemid 38899703)
40. T Kinashi K Katagiri 2004 Regulation of lymphocyte adhesion and migration by the small GTPase Rap1 and its effector molecule, RAPL Immunol Lett 93 1 5 15134891 10.1016/j.imlet.2004.02.008 1:CAS:528:DC%2BD2cXjvVeqs7c%3D (Pubitemid 38591512)
41. H Fujita S Fukuhara A Sakurai A Yamagishi Y Kamioka Y Nakaoka M Masuda N Mochizuki 2005 Local activation of Rap1 contributes to directional vascular endothelial cell migration accompanied by extension of microtubules on which RAPL, a Rap1-associating molecule, localizes J Biol Chem 280 5022 5031 15569673 10.1074/jbc.M409701200 1:CAS:528:DC%2BD2MXhtVymur8%3D (Pubitemid 40288678)
42. M Takahashi Y Rikitake Y Nagamatsu T Hara W Ikeda K Hirata Y Takai 2008 Sequential activation of Rap1 and Rac1 small G proteins by PDGF locally at leading edges of NIH3T3 cells Genes Cells 13 549 569 18422604 10.1111/j.1365-2443.2008.01187.x 1:CAS:528:DC%2BD1cXntlams7w%3D (Pubitemid 351761773)
43. M Itoh CM Nelson CA Myers MJ Bissell 2007 Rap1 integrates tissue polarity, lumen formation, and tumorigenic potential in human breast epithelial cells Cancer Res 67 4759 4766 17510404 10.1158/0008-5472.CAN-06-4246 1:CAS:528:DC%2BD2sXltl2gs7s%3D (Pubitemid 46910183)
44. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 Reporting recommendations for tumor marker prognostic studies (remark) Exp Oncol 28 99 105 16837898 1:STN:280:DC%2BD28vhsFOktg%3D%3D (Pubitemid 44140259)
45. KF Becker C Schott S Hipp V Metzger P Porschewski R Beck J Nahrig I Becker H Hofler 2007 Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis J Pathol 211 370 378 17133373 10.1002/path.2107 1:CAS:528: DC%2BD2sXisFyksb4%3D (Pubitemid 46172713)
46. KS McCarty Jr E Szabo JL Flowers EB Cox GS Leight L Miller J Konrath JT Soper DA Budwit WT Creasman 1986 Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors Cancer Res 46 4244s 4248s 3524805 (Pubitemid 16041242)
47. M Cregger AJ Berger DL Rimm 2006 Immunohistochemistry and quantitative analysis of protein expression Arch Pathol Lab Med 130 1026 1030 16831029 1:CAS:528:DC%2BD28XnslKnsLo%3D (Pubitemid 44061434)
48. MA Guvakova 2007 Insulin-like growth factors control cell migration in health and disease Int J Biochem Cell Biol 39 890 909 17113337 10.1016/j.biocel.2006.10.013 1:CAS:528:DC%2BD2sXksFaisbo%3D (Pubitemid 46575318)
49. J Zha MR Lackner 2010 Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy Clin Cancer Res 16 2512 2517 20388853 10.1158/1078-0432.CCR-09-2232 1:CAS:528:DC%2BC3cXltlegtr0%3D
50. K Polyak 2002 Molecular alterations in ductal carcinoma in situ of the breast Curr Opin Oncol 14 92 96 11790987 10.1097/00001622-200201000-00016 1:CAS:528:DC%2BD38XnsVSqsw%3D%3D (Pubitemid 34072970)
51. L Wiechmann HM Kuerer 2008 The molecular journey from ductal carcinoma in situ to invasive breast cancer Cancer 112 2130 2142 18383519 10.1002/cncr.23430 (Pubitemid 351628621)
52. D Lann D LeRoith 2008 The role of endocrine insulin-like growth factor-I and insulin in breast cancer J Mammary Gland Biol Neoplasia 13 371 379 19030972 10.1007/s10911-008-9100-x
53. B Schnarr K Strunz J Ohsam A Benner J Wacker D Mayer 2000 Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer Int J Cancer 89 506 513 11102895 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F 1:CAS:528:DC%2BD3cXptVejs74%3D
54. JP Peyrat J Bonneterre R Beuscart J Djiane A Demaille 1988 Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors Cancer Res 48 6429 6433 2972358 1:CAS:528: DyaL1MXlsFWi
55. RA Jones CI Campbell EJ Gunther LA Chodosh JJ Petrik R Khokha RA Moorehead 2007 Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation Oncogene 26 1636 1644 16953219 10.1038/sj.onc.1209955 1:CAS:528:DC%2BD2sXisFynsb4%3D (Pubitemid 46398739)
56. JE Kucab SE Dunn 2003 Role of IGF-1R in mediating breast cancer invasion and metastasis Breast Dis 17 41 47 15687676 1:CAS:528:DC%2BD2cXnsFGktQ%3D%3D (Pubitemid 38180807)
57. FM Waldman S De Vries KL Chew DH Moore K Kerlikowske BM Ljung 2000 Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences J Natl Cancer Inst 92 313 320 10675380 10.1093/jnci/92.4.313 1:STN:280:DC%2BD3c7ktFCmsw%3D%3D (Pubitemid 30117734)
58. BS Miller D Yee 2005 Type I insulin-like growth factor receptor as a therapeutic target in cancer Cancer Res 65 10123 10127 16287993 10.1158/0008-5472.CAN-05-2752 1:CAS:528:DC%2BD2MXht1WgurjF (Pubitemid 41743697)
59. D Yee 2007 Targeting insulin-like growth factor pathways Br J Cancer 96 Supp l 7 10
60. J Rodon V De Santos RJ Ferry Jr R Kurzrock 2008 Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials Mol Cancer Ther 7 2575 2588 18790742 10.1158/1535-7163.MCT-08-0265 1:CAS:528:DC%2BD1cXhtFSms7jJ
61. RB Lobell D Liu CA Buser JP Davide E De Puy K Hamilton KS Koblan Y Lee S Mosser SL Motzel JL Abbruzzese CS Fuchs EK Rowinsky EH Rubin S Sharma PJ Deutsch KE Mazina BW Morrison L Wildonger SL Yao NE Kohl 2002 Preclinical and clinical pharmacodynamic assessment of L-778, 123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I Mol Cancer Ther 1 747 758 12479371 1:CAS:528:DC%2BD38XlsFSmtb8%3D
62. J Sun J Ohkanda D Coppola H Yin M Kothare B Busciglio AD Hamilton SM Sebti 2003 Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice Cancer Res 63 8922 8929 14695209 1:CAS:528:DC%2BD3sXhtVSqtbjN (Pubitemid 38064072)